NCT00093990 2016-09-14
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.